combination therapy

2:45
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
1:57
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
1:04
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
04:20
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:53
Oral azacitidine plus R-CHOP for previously untreated NHL
John Leonard
1:05
Lessons in lymphoma: highlights in the field of NHL
John Leonard
2:25
Analyzing AML: novel therapies in review
Farhad Ravandi
1:33
PD-1 & PDL-1 combinations with CAR T-cell therapy
David Maloney
6:57
Key updates in MPNs from ASH 2018
Claire Harrison
1:06
Current hurdles in the treatment of CLL
Lindsey Roeker
0:55
CAR-T and ibrutinib in combination: a promising treatment for CLL
Lydia Scarfò
2:20
Investigating ibrutinib for CLL: IciCLLe & CLARITY
Peter Hillmen
4:01
CLL trial updates: ALLIANCE & iLLUMINATE
Barbara Eichhorst
2:36
iFCG for the frontline treatment of IGHV-mutated CLL: trial update
Nitin Jain
2:24
Better together? Ibrutinib and venetoclax for high-risk CLL
Nitin Jain
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals